Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;102(8):e297-e299.
doi: 10.3324/haematol.2017.168740. Epub 2017 May 11.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Simone Claudiani  1 , Jane F Apperley  2 , Robert Peter Gale  2 , Richard Clark  3 , Richard Szydlo  2 , Simona Deplano  2 , Renuka Palanicawandar  2 , Jamshid Khorashad  2 , Letizia Foroni  2 , Dragana Milojkovic  2
Affiliations

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Simone Claudiani et al. Haematologica. 2017 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence of molecular relapse after tyrosine kinase inhibitor (TKI) interruption. Cumulative incidence of molecular relapse (MR3 loss) after TKI interruption for the entire patient cohort [black line, 46%; 95% Confidence Interval (CI): 31, 60%] and according to transcript type (for e13a2, red dashed line, 64%, 95%CI: 50, 77%; for e14a2, blue dashed line, 35%, 95%CI: 15, 56%). Dotted lines represent confidence intervals.
See this image and copyright information in PMC

References

    1. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035. - PubMed
    1. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–430. - PubMed
    1. Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5(9):2398–2411. - PMC - PubMed
    1. Mahon FX, Richter J, Guilhot J, et al. Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. Blood. 2016;128(22):787.
    1. Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999–1003. - PMC - PubMed

Publication types